Prospective evaluation of the use of antigen-specific immune complexes in predicting the development of recurrent melanoma.

We previously demonstrated that the antigen-specific immune complexes captured by the monoclonal antibody MAb JSI in a sandwich enzyme-linked immunosorbent assay were associated with recurrent melanoma. To determine the potential use of antigen-specific immune complex analysis in predicting the development of recurrent melanoma, we prospectively analyzed serum obtained from patients with melanoma following surgical treatment. Two hundred fifty-three patients have been followed up for a median of 25 months (range, 17 to 29 months). Seventy-seven patients (30%) have developed recurrent melanoma. Antigen-specific immune complexes correlated with the stage of disease at time of entry into the study. The absence of antigen-specific immune complexes in postoperative serum samples is predictive of a disease-free status. Long-term follow-up will define the false-positive rate of antigen-specific immune complex analysis. Continued refinement of this approach should lead to clinically useful methodology to monitor human melanoma.

[1]  R. Saxton,et al.  Immunochemical characterization of a tumor-associated antigen defined by a monoclonal antibody. , 1990, Journal of Surgical Research.

[2]  R. Saxton,et al.  Detection and isolation of antigen‐specific immune complexes from sera of melanoma patients , 1990, International journal of cancer.

[3]  R. Gupta,et al.  Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma. , 1990, Archives of surgery.

[4]  R. Gupta,et al.  Active specific immunotherapy in malignant melanoma. , 1989, Seminars in surgical oncology.

[5]  R. Gupta,et al.  Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma. , 1986, Archives of surgery.

[6]  F. Meyskens,et al.  Clinical-biologic patterns of metastatic melanoma and their effect on treatment. , 1985, Cancer treatment reports.

[7]  V. Le Doussal,et al.  Prognostic index for clinical Stage I cutaneous malignant melanoma. , 1983, Cancer research.

[8]  C. Balch,et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Brickenden,et al.  Human melanoma‐specific oncofetal antigen defined by a mouse monoclonal antibody , 1982, International journal of cancer.

[10]  N. Cascinelli,et al.  A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma , 1982 .

[11]  R. Elashoff,et al.  Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. , 1982 .

[12]  M. Mihm,et al.  A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. , 1981, American journal of surgery.

[13]  J. Brown,et al.  Two human tumor‐associated antigens, p155 and p210, detected by monoclonal antibodies , 1981, International journal of cancer.

[14]  H. Luthra,et al.  Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer , 1981, International journal of cancer.

[15]  M. Mihm,et al.  A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. , 1981, Surgery.

[16]  M. Mihm,et al.  A Prognostic Model for Clinical Stage I Melanoma of the Upper Extremity. The Importance of Anatomic Subsites in Predicting Recurrent Disease , 1981, Annals of surgery.

[17]  M C Mihm,et al.  Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes , 1981, Cancer.

[18]  L. Old.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. , 1981, Cancer research.

[19]  Institut Gustave Roussy,et al.  Prognosis of stage I melanoma of the skin. Who collaborating centres for evaluation of methods of diagnosis and treatment of melanoma , 1980, International journal of cancer.

[20]  H. Koprowski,et al.  Biochemical characterization of human melanoma cell surfaces: dissection with monoclonal antibodies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Brown,et al.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Rosenberg.  Serologic analysis of human cancer antigens , 1980 .

[23]  C. Balch,et al.  Tumor thickness as a guide to surgical management of clinical stage I melanoma patients , 1979, Cancer.

[24]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: Prognostic Histopathological Features Comparing Clark's and Breslow's Staging Methods , 1978, Annals of surgery.

[25]  S. Rosenberg,et al.  Prognostic Factors in Patients Undergoing Lymphadenectomy of Malignant Melanoma , 1977, Annals of surgery.

[26]  H. Wanebo,et al.  Selection of the Optimum Surgical Treatment of Stage I Melanoma By Depth of Microinvasion: Use of the Combined Microstage Technique (Clark‐Breslow) , 1975, Annals of surgery.

[27]  L. Einhorn,et al.  Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. , 1974, Cancer research.

[28]  E. Engvall,et al.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. , 1972, Journal of immunology.